Comparison of characteristics which may predispose to iron deficiency
| Aetiology/gender | Proportion on anticoagulation | Proportion on ERAs | Proportion with saturation <95% on air |
| IPAH all | 67/85 (78.8%) | 30/85 (35.3%) | 35/85 (41.2%) |
| CTEPH all | 120/120 (100.0%) | 57/120 (47.5%) | 60/120 (50.0%) |
| p<0.001 | p=0.09 | p=0.26 | |
| IPAH pre-menopausal women | 22/26 (84.6%) | 13/26 (50.0%) | 9/26 (34.6%) |
| CTEPH pre-menopausal women | 26/26 (100.0%) | 9/26 (34.6%) | 7/26 (26.9%) |
| p=0.11 | p=0.4 | p=0.76 | |
| IPAH post-menopausal women | 27/34 (79.4%) | 8/34 (23.5%) | 14/34 (41.2%) |
| CTEPH post-menopausal women | 46/46 (100.0%) | 29/46 (63.0%) | 30/46 (65.2%) |
| p=0.002 | p<0.001 | p=0.04 | |
| IPAH men | 18/25 (72.0%) | 9/25 (36.3%) | 12/25 (48.0%) |
| CTEPH men | 48/48 (100.0%) | 19/48 (39.6%) | 23/48 (47.9%) |
| p<0.001 | p=0.80 | p=1.0 | |
| IPAH+BMPR2 mutations | 7/10 (70.0%)* | 4/10 (40.0%)* | 2/10 (20.0%)* |
↵* Unable to calculate a p value as no comparable group of CTEPH patients with BMPR2 mutations.
BMPR2, bone morphogenetic protein receptor type 2; CTEPH, chronic thromboembolic pulmonary hypertension; ERA, endothelin receptor antagonist; IPAH, idiopathic pulmonary arterial hypertension.